X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs GLENMARK PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. GLENMARK PHARMA FRESENIUS KABI ONCO./
GLENMARK PHARMA
 
P/E (TTM) x 22.1 13.9 159.7% View Chart
P/BV x 3.1 3.9 80.2% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 FRESENIUS KABI ONCO.   GLENMARK PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
GLENMARK PHARMA
Mar-16
FRESENIUS KABI ONCO./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,262 13.9%   
Low Rs79672 11.7%   
Sales per share (Unadj.) Rs37.7270.6 13.9%  
Earnings per share (Unadj.) Rs5.124.9 20.5%  
Cash flow per share (Unadj.) Rs6.734.4 19.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs42.5151.3 28.1%  
Shares outstanding (eoy) m158.23282.16 56.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.6 94.5%   
Avg P/E ratio x25.038.9 64.3%  
P/CF ratio (eoy) x18.928.1 67.4%  
Price / Book Value ratio x3.06.4 46.8%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m20,135272,778 7.4%   
No. of employees `0001.210.0 11.5%   
Total wages/salary Rs m70313,782 5.1%   
Avg. sales/employee Rs Th5,176.27,614.9 68.0%   
Avg. wages/employee Rs Th610.41,374.8 44.4%   
Avg. net profit/employee Rs Th699.6700.2 99.9%   
INCOME DATA
Net Sales Rs m5,96376,340 7.8%  
Other income Rs m18356 5.1%   
Total revenues Rs m5,98176,696 7.8%   
Gross profit Rs m1,43014,172 10.1%  
Depreciation Rs m2582,691 9.6%   
Interest Rs m-261,789 -1.5%   
Profit before tax Rs m1,21610,048 12.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3423,028 11.3%   
Profit after tax Rs m8067,019 11.5%  
Gross profit margin %24.018.6 129.2%  
Effective tax rate %28.130.1 93.4%   
Net profit margin %13.59.2 147.0%  
BALANCE SHEET DATA
Current assets Rs m5,10259,096 8.6%   
Current liabilities Rs m2,38540,018 6.0%   
Net working cap to sales %45.625.0 182.3%  
Current ratio x2.11.5 144.8%  
Inventory Days Days15075 200.1%  
Debtors Days Days113119 95.1%  
Net fixed assets Rs m5,14839,075 13.2%   
Share capital Rs m158282 56.1%   
"Free" reserves Rs m6,55630,281 21.6%   
Net worth Rs m6,73242,703 15.8%   
Long term debt Rs m95224,873 3.8%   
Total assets Rs m10,388111,026 9.4%  
Interest coverage x-45.86.6 -691.9%   
Debt to equity ratio x0.10.6 24.3%  
Sales to assets ratio x0.60.7 83.5%   
Return on assets %7.57.9 94.6%  
Return on equity %12.016.4 72.8%  
Return on capital %14.617.5 83.4%  
Exports to sales %74.543.3 172.0%   
Imports to sales %24.87.4 333.4%   
Exports (fob) Rs m4,44133,044 13.4%   
Imports (cif) Rs m1,4775,672 26.0%   
Fx inflow Rs m5,29836,945 14.3%   
Fx outflow Rs m1,77261,066 2.9%   
Net fx Rs m3,525-24,122 -14.6%   
CASH FLOW
From Operations Rs m1,2743,449 36.9%  
From Investments Rs m-1,204-8,802 13.7%  
From Financial Activity Rs m-1966,986 -2.8%  
Net Cashflow Rs m-126934 -13.5%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 6.9 4.3%  
FIIs % 9.6 34.4 27.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   42,599 56,727 75.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ALEMBIC PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS